SELLAS REGAL Trial Reaches 80th Event: The GPS AML Readout Is Now the Trade
SELLAS reached the 80th event in the Phase 3 REGAL trial of GPS in AML. The milestone unlocks final analysis, but it is not an efficacy result.
SELLAS reached the milestone the market was waiting for
SELLAS Life Sciences said on October 28, 2026 that its Phase 3 REGAL trial of galinpepimut-S, or GPS, reached the pre-specified 80th event. In this event-driven study, the event is a death, not a response or remission. Reaching that threshold allows the company to proceed with database lock, unblinding, and the final statistical analysis of the primary endpoint. SELLAS said it expects to report topline results during the fourth quarter of 2026.
That is a real clinical milestone. It is not an efficacy result. Investors now have a defined readout window, but they still do not know whether GPS improves overall survival against investigator’s choice of best available therapy.
What REGAL is testing
REGAL is a randomized Phase 3 study in patients with acute myeloid leukemia who reached a second or later complete remission, or a comparable remission with incomplete platelet recovery, after second-line salvage therapy. The trial compares GPS maintenance monotherapy with investigator’s choice of best available therapy. Its primary question is overall survival.
This is a difficult setting. Patients who reach a second remission remain at high risk of relapse, and the treatment population is narrower than the broad AML market. A positive result would therefore matter clinically, but the commercial opportunity must be modeled around the actual post-relapse population rather than the total number of people diagnosed with AML.
The 80th event reduces timeline uncertainty, not clinical risk
Before the announcement, the main uncertainty was when the trial would accumulate enough events to produce its final analysis. That uncertainty is now smaller. The remaining uncertainty is more important: the size, reliability, and clinical meaning of the survival difference between GPS and the control arm.
The event threshold does not tell investors whether the hazard ratio will cross the study’s success boundary. It does not establish statistical significance, a favorable benefit-risk profile, or a path to approval. Those conclusions require the locked database, the pre-specified analysis, and the company’s disclosure of the topline data.
There is also a timing distinction. SELLAS said it expects preliminary topline primary-endpoint results this quarter. Topline results may answer the main efficacy question, but investors will still need the full dataset, including safety, censoring, subgroup consistency, follow-up duration, and the regulatory path.
Why GPS could matter if the result is positive
GPS is designed as an immunotherapeutic approach directed at Wilms’ tumor 1, a target associated with multiple cancers. A positive REGAL result could give SELLAS a late-stage product candidate in an AML setting where maintenance therapy after a second remission has substantial unmet need.
The strongest bull case is not simply that GPS is novel. It is that a statistically persuasive overall-survival result in this population could support a focused regulatory and commercial strategy. SELLAS would still need to translate the result into a filing, approval, manufacturing readiness, physician adoption, and reimbursement. But a clean Phase 3 survival result would remove the largest scientific risk facing the program.
The bear case remains straightforward
The 80th event announcement contains no efficacy data. GPS could fail to meet the primary endpoint, show a small or inconsistent effect, or produce a result that is statistically positive but difficult to commercialize. AML studies can also be difficult to interpret when patient characteristics, salvage regimens, transplant history, and subsequent therapies differ across arms.
A second risk is concentration. REGAL is the company’s most important near-term value driver. SELLAS is also developing SLS009 in AML, but that program remains earlier stage. The company’s August 2026 update reported $138.3 million in cash and cash equivalents at June 30, 2026, while its Form 10-Q reported 201.9 million common shares outstanding as of August 10. Those resources may support the readout period, but a negative result would make future financing and dilution more relevant to the valuation.
What investors should watch in the readout
- Overall survival: the treatment effect, confidence interval, and p-value compared with the pre-specified analysis plan.
- Control-arm performance: the therapies selected as best available therapy and whether the control outcomes match the assumptions behind the study design.
- Consistency: whether the result holds across important patient subgroups rather than depending on one small segment.
- Safety and treatment exposure: discontinuations, adverse events, treatment duration, and whether the benefit is large enough to justify maintenance therapy.
- Regulatory language: whether SELLAS describes a clear submission path, requests additional evidence, or says the result requires further discussion with regulators.
- Financing: whether the company can fund the next regulatory and development steps without a near-term equity raise.
Bottom line
SELLAS has crossed the operational milestone that unlocks the REGAL final analysis. That makes the next few weeks more important, but it does not make the outcome more certain.
For SLS shareholders, the setup is now binary in a way that many development-stage biotech catalysts are not: a credible overall-survival result could validate GPS and change the company’s financing and regulatory position, while a weak or negative result would leave a cash-burning company with earlier-stage assets and a more difficult capital-markets problem. The 80th event is the catalyst. The data are the investment thesis.
Sources
SELLAS Life Sciences: REGAL reaches the 80th event, October 28, 2026
SELLAS second-quarter 2026 financial results and corporate update
SELLAS Form 10-Q for the quarter ended June 30, 2026
ClinicalTrials.gov: REGAL, NCT04229979
Informational disclaimer: This article is for informational purposes only and is not investment advice. Clinical-stage biotechnology investments can lose most or all of their value. Read the company’s filings, trial disclosures, and future topline data before making any investment decision.